FILE:AMGN/AMGN-8K-20091005165636.txt.gz
EVENTS:	Termination of a Material Definitive Agreement
TEXT:
ITEM: Termination of a Material Definitive Agreement
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
Item 1.02 Termination of a Material Definitive Agreement.
On September 30, 2009, the Enbrel Supply Agreement, as amended, by and among Immunex Corporation, Wyeth, acting through its Wyeth Pharmaceuticals Division (formerly American Home Products Corporation, acting through its Wyeth-Ayerst Pharmaceuticals Division) and Boehringer Ingelheim Pharma KG, dated November 5, 1998 was terminated by all parties.
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: October 5, 2009
 


